Alpha-2 adrenergic receptor (ADRA2) (ADRA2)

The Alpha-2 adrenergic receptor is a member of the G protein-coupled receptor (GPCR) superfamily that mediates the physiological responses to the catecholamines norepinephrine and epinephrine [1]. These receptors are primarily coupled to the Gi/o signaling pathway, leading to the inhibition of adenylyl cyclase and a subsequent decrease in intracellular cyclic AMP (cAMP) levels [2]. They play a critical role in the central and peripheral nervous systems by acting as presynaptic autoreceptors that provide feedback inhibition of neurotransmitter release, particularly norepinephrine [3]. Clinically, alpha-2 adrenergic receptors are targeted for a variety of conditions including hypertension, attention-deficit hyperactivity disorder (ADHD), chronic pain, and as sedative agents in intensive care settings [4]. Agonists like clonidine and dexmedetomidine are used for their sympatholytic and analgesic properties, while antagonists are explored for their potential in treating depression and erectile dysfunction [5]. Understanding the subtype-specific roles (Alpha-2A, 2B, and 2C) is a major focus of current drug development to improve therapeutic efficacy and reduce side effects like sedation and hypotension [6].

Other names

Alpha-2 adrenoceptorAlpha-2 ARADRA2α2-adrenergic receptorAlpha-2A adrenergic receptorAlpha-2B adrenergic receptorAlpha-2C adrenergic receptor

Alpha-2 adrenergic receptor agonists bind to the receptor, activating Gi/o proteins which inhibit adenylyl cyclase and reduce cAMP levels, leading to decreased neurotransmitter release and sympatholytic effects. Antagonists block these receptors to increase sympathetic outflow or modulate neurotransmission in the central nervous system.